Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: interim results from two ongoing open-label studies

Gil-Nagel, A., Brodie, M.J., Leroy, R., Cyr, T., Hall, S., Castiglia, M., Twomey, C. and VanLandingham, K. (2012) Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: interim results from two ongoing open-label studies. Epilepsy Research, 102(1-2), pp. 117-121. (doi: 10.1016/j.eplepsyres.2012.05.007)

Abstract

Interim results of two open-label extension studies assessed ezogabine/retigabine safety and tolerability for partial-onset seizures. At data cutoff, 336 (60%) patients received ≥12 months’ open-label ezogabine/retigabine. The most common TEAEs included dizziness (22%), somnolence (19%), headache (14%), and fatigue (10%). Change in seizure frequency from baseline (median reduction, 53%) and responder rate (52.5%) was maintained in patients remaining on ezogabine/retigabine. Continuous 6-month and 12-month seizure-free rates for ezogabine/retigabine exposures ≥12 months were 13.1% and 7.1%, respectively.

• Item Type: Articles
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Brodie, Professor Martin
• Authors: Gil-Nagel, A., Brodie, M.J., Leroy, R., Cyr, T., Hall, S., Castiglia, M., Twomey, C., and VanLandingham, K.
• College/School: College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
• Journal Name: Epilepsy Research
• ISSN: 0920-1211